56.07
1.34 (2.45%)
| Penutupan Terdahulu | 54.73 |
| Buka | 54.75 |
| Jumlah Dagangan | 2,148,569 |
| Purata Dagangan (3B) | 2,179,862 |
| Modal Pasaran | 6,909,001,216 |
| Harga / Pendapatan (P/E TTM) | 14.91 |
| Harga / Pendapatan (P/E Ke hadapan) | 11.22 |
| Harga / Jualan (P/S) | 6.48 |
| Harga / Buku (P/B) | 13.94 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 - 8 Aug 2025 |
| Margin Keuntungan | 44.76% |
| Margin Operasi (TTM) | 53.44% |
| EPS Cair (TTM) | 3.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 35.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 53.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 318.67% |
| Nisbah Semasa (MRQ) | 8.39 |
| Aliran Tunai Operasi (OCF TTM) | 503.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 402.43 M |
| Pulangan Atas Aset (ROA TTM) | 18.50% |
| Pulangan Atas Ekuiti (ROE TTM) | 147.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Halozyme Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.38 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.17% |
| % Dimiliki oleh Institusi | 102.21% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 72.00 (HC Wainwright & Co., 28.41%) | Beli |
| Median | 62.00 (10.58%) | |
| Rendah | 47.00 (Leerink Partners, -16.18%) | Jual |
| Purata | 60.80 (8.44%) | |
| Jumlah | 1 Beli, 3 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 56.06 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 29 May 2025 | 72.00 (28.41%) | Beli | 54.73 |
| 25 Apr 2025 | 72.00 (28.41%) | Beli | 60.49 | |
| Morgan Stanley | 14 May 2025 | 62.00 (10.58%) | Pegang | 47.91 |
| Leerink Partners | 13 May 2025 | 47.00 (-16.18%) | Jual | 50.23 |
| Wells Fargo | 07 May 2025 | 65.00 (15.93%) | Pegang | 70.14 |
| JP Morgan | 21 Apr 2025 | 58.00 (3.44%) | Pegang | 57.29 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |